Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Twist Bioscience Corp

Ticker
TWST
Sector
Industry
Report date
November 16, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Twist Bioscience's record fiscal 2026 revenue and detailed disclosures from its Q4 2026 earnings call, reflecting ongoing business execution and market engagement.

Recent developments:
  • Twist Bioscience reported record fiscal 2026 revenue of $459.4 million, with diversified revenue contributions across therapeutics, diagnostics, academic research, global supply partners, and industry sectors [N1].
  • The company held a Q4 2026 earnings call providing highlights and a transcript detailing operational and financial results, including a reported loss but revenue exceeding prior periods [N2][N3][N4].
  • Twist continues to expand its product offerings and customer base leveraging its proprietary silicon-based DNA synthesis platform, supporting applications in AI-enabled drug discovery and next-generation sequencing workflows [N2][N3].
Overview

Twist Bioscience Corporation develops and commercializes synthetic DNA and related biological products using a proprietary silicon-based platform that miniaturizes DNA synthesis reactions on silicon chips. This platform enables the parallel synthesis of over one million unique DNA sequences per chip with high precision and reduced chemical usage. The company’s products serve a broad range of applications including therapeutics drug discovery, diagnostics, industrial enzyme engineering, agriculture, and academic research. Twist’s two main product groups are DNA Synthesis and Protein Solutions, which include synthetic genes, oligonucleotide pools, protein expression, and antibody characterization, and NGS Applications, which provide tools for next-generation sequencing workflows such as target enrichment and library preparation. The company’s customer base spans biotech, pharma, diagnostics companies, research institutions, and agricultural biotechnology firms globally. Twist reported fiscal 2026 revenue of $459.4 million and maintains strong liquidity and capital resources as of September 2026.

Executive summary

Twist Bioscience Corporation is a synthetic biology company that manufactures synthetic DNA and related biological products using a proprietary silicon-based DNA synthesis platform. The company serves approximately 4,100 customers globally across therapeutics, diagnostics, industrial, agriculture, academic research, and government sectors. In fiscal 2026, Twist reported record revenue of $459.4 million, with diversified revenue streams across therapeutics, diagnostics, academic research, global supply partners, and industry applications. The company operates two main product groups: DNA Synthesis and Protein Solutions, and NGS Applications, both leveraging its integrated technology platform to deliver high-quality, scalable, and cost-effective solutions. As of September 30, 2026, Twist held strong liquidity with $534 million in cash and equivalents and a current ratio of 5.86. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for TWST

Bull case model:

Twist Bioscience’s integrated silicon-based DNA synthesis platform supports a wide range of applications across growing markets including therapeutics, diagnostics, industrial enzyme engineering, and agriculture. The company’s expansion into AI-enabled drug discovery and protein characterization services complements its DNA synthesis offerings, potentially increasing customer engagement and revenue diversification. Record fiscal 2026 revenue of $459.4 million and a broad global customer base of approximately 4,100 customers demonstrate market acceptance and scalability. Strong liquidity and capital resources provide financial flexibility to invest in product development and market expansion. The company’s focus on innovation and expanding its product portfolio within a large and growing serviceable addressable market supports its strategic growth initiatives.

Bear case model:

Twist Bioscience operates in highly competitive and rapidly evolving markets where technological advances and customer preferences may shift. The company reported a net loss of $130.2 million in fiscal 2026, reflecting ongoing investments and operational costs that may pressure profitability. Market estimates and growth assumptions rely on third-party data and internal forecasts that may not materialize as anticipated. Dependence on a proprietary platform exposes the company to risks related to technological obsolescence or manufacturing disruptions. Additionally, regulatory, supply chain, and competitive risks inherent in the synthetic biology and life sciences sectors could adversely affect business performance.

Moat:

Twist Bioscience’s moat is anchored in its proprietary silicon-based DNA synthesis platform that enables high-throughput, precise, and cost-efficient production of synthetic DNA compared to legacy methods. This platform integrates expertise in silicon, software, fluidics, chemistry, and automation, allowing the company to manufacture millions of unique DNA sequences in parallel with reduced chemical consumption. The scalability and versatility of this platform support a broad product portfolio across multiple life sciences markets, including therapeutics, diagnostics, industrial applications, and agriculture. The company’s integrated technology and manufacturing infrastructure, combined with its expanding product offerings and customer base, create barriers to entry for competitors relying on traditional DNA synthesis methods. Additionally, Twist’s ability to serve emerging markets such as AI-enabled drug discovery and next-generation sequencing sample preparation further strengthens its competitive position.

Risks overview
Risks summary
The primary risks for Twist Bioscience include technological and manufacturing challenges related to its proprietary platform, ongoing financial losses impacting profitability, competitive pressures in dynamic markets, and regulatory and supply chain uncertainties.
Risks details:

• Technological and Manufacturing Risks: Reliance on proprietary silicon-based DNA synthesis technology exposes the company to risks of technological obsolescence, manufacturing disruptions, or failure to maintain competitive advantages.
• Financial Performance and Profitability: The company reported significant net losses in fiscal 2026, indicating ongoing challenges in achieving profitability amid investments in growth and product development.
• Market and Competitive Risks: Twist operates in competitive markets with evolving customer needs and emerging technologies that could impact demand for its products and services.
• Regulatory and Supply Chain Risks: The company faces risks related to regulatory compliance, supply chain constraints, and potential disruptions that could affect operations and product delivery.

FINAL FORECAST FOR TWST

Final take one line
Twist Bioscience demonstrates very high visibility with detailed disclosures on its proprietary DNA synthesis platform, diversified product offerings, and record fiscal 2026 revenue amid ongoing investments and market expansion.
Final take 12 to 24 month view

Business trends: Expansion of product portfolio leveraging proprietary silicon-based DNA synthesis platform across therapeutics, diagnostics, AI-enabled drug discovery, and NGS applications.
Execution milestones: Record fiscal 2026 revenue of $459.4 million, broadening customer base to approximately 4,100, and integration of protein solutions with DNA synthesis products.
Key risks: Technological obsolescence, ongoing net losses impacting profitability, competitive market dynamics, and regulatory and supply chain uncertainties.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Twist Bioscience Corporation provides customizable synthetic DNA and related biological solutions across diagnostics, therapeutics, industrial, agriculture, and research markets [S1].
  • The company’s proprietary platform manufactures synthetic DNA by writing DNA on silicon chips, enabling high throughput, precision, and cost efficiency compared to legacy methods [S1].
  • Twist serves approximately 4,100 global customers across multiple industries including therapeutics, diagnostics, industrial chemicals, agriculture, academic research, and government [S1].
  • Revenue for fiscal 2026 was $459.4 million, with breakdowns including $162.3 million from therapeutics, $164.3 million from diagnostics, $56.6 million from academic research and government, $52.0 million from global supply partners, and $24.2 million from industry and applied markets [S1][N1].
  • The company operates two main product groups: DNA Synthesis and Protein Solutions, and NGS Applications, both leveraging the silicon-based DNA synthesis platform [S1].
  • DNA Synthesis and Protein Solutions include synthetic genes, oligonucleotide pools, protein expression, antibody characterization, and biologics discovery solutions, supporting traditional and AI-enabled drug discovery [S1].
  • NGS Applications products support next-generation sequencing workflows including target enrichment panels, library preparation kits, and synthetic controls, serving primarily diagnostic companies and research institutions [S1].
  • Twist’s platform miniaturizes chemical DNA synthesis reactions, enabling synthesis of over 1 million oligonucleotides per silicon chip with reduced chemical use and high accuracy [S1].
  • The company’s market estimates indicate a combined serviceable addressable market exceeding $13 billion by 2030, split between NGS Applications (~$6 billion SAM) and DNA Synthesis and Protein Solutions (~$7 billion SAM) [S1].
  • Fiscal 2026 net loss was $130.2 million with basic and diluted EPS of -$2.08 as of September 30, 2026 [S1].
  • Liquidity as of September 30, 2026, includes $534.0 million in cash and equivalents, $47.9 million in short-term investments, current assets of $737.2 million, current liabilities of $125.8 million, a current ratio of 5.86, and a cash ratio of 4.63 [S1].
  • Recent news highlights include reporting record fiscal 2026 revenue and Q4 2026 earnings call details, with Q4 revenue exceeding prior periods despite a reported loss [N1][N2][N3][N4].
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-11-16 | 10-K
  • S2 | 2026-08-03 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Twist Bioscience Reports Record Fiscal 2026 Revenue of $459.4 million | https://www.nasdaq.com/articles/twist-bioscience-reports-record-fiscal-2026-revenue-4594-million
  • N2 | 2026-11-12 | www.nasdaq.com | Twist Bioscience Q4 Earnings Call Highlights | https://www.nasdaq.com/articles/twist-bioscience-q4-earnings-call-highlights
  • N3 | 2026-11-12 | www.nasdaq.com | Twist Bioscience (TWST) Q4 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/twist-bioscience-twst-q4-2026-earnings-call-transcript
  • N4 | 2026-11-12 | www.nasdaq.com | Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/twist-bioscience-twst-reports-q4-loss-beats-revenue-estimates
  • N5 | 2026-11-09 | www.nasdaq.com | ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/adc-therapeutics-sa-adct-reports-q3-loss-tops-revenue-estimates
  • N6 | 2026-11-05 | www.nasdaq.com | ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-surpasses-q3-earnings-and-revenue-estimates
  • N7 | 2026-11-03 | www.nasdaq.com | Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/beam-therapeutics-inc-beam-reports-q3-loss-misses-revenue-estimates
  • N8 | 2026-08-03 | www.nasdaq.com | Twist Bioscience (TWST) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/twist-bioscience-twst-reports-q3-loss-beats-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine